Chris is a seasoned pharmaceutical executive bringing more than 20 years of pharmaceutical operations and business development expertise to BrYet. Drawing from transactional experiences spanning the breadth of life science verticals, Chris’ primary focus spans pharma/biotech, medical device, and digital health across the life sciences segments. 

 

Chris has advised dozens of senior management teams on a variety of complex strategic BD&L issues, ranging from transaction process considerations to valuation and transaction structure, value proposition communication and buyer/seller analysis, along with the plethora of managerial challenges faced in executing complex corporate transactions.  Chris’ focus is servicing pharma clients and leading transformation transactions including, but not limited to, funding/financing efforts, drug development plans, commercialization strategies, asset in-licensing and/or out-licensing, expansion of development pipelines, mergers & acquisitions, joint venture transactions, and leading all partnering and licensing efforts within the pharmaceutical and biotechnology healthcare segments.

 

Previously, Chris was the Chief Operating Officer and VP of Business Development at TFF Pharmaceuticals. Chris is also the managing director of a BD&L consulting company, C2 Strategic Solutions, which has provided BD&L services to the pharma, biotechnology, science and drug delivery industries.

 

Chris is based out of Princeton, NJ and holds a bachelor’s degree in finance from Villanova University and a master’s degree in business management from Rider University.